{
    "clinical_study": {
        "@rank": "45149", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A - LY2886721", 
                "arm_group_type": "Experimental", 
                "description": "Alzheimer's disease (AD) participants will receive a 70 mg single oral dose of LY2886721."
            }, 
            {
                "arm_group_label": "Cohort A - Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "AD participants will receive a single oral dose of placebo."
            }, 
            {
                "arm_group_label": "Cohort B - LY2886721", 
                "arm_group_type": "Experimental", 
                "description": "Healthy participants will receive a single 70 mg oral dose of LY2886721."
            }, 
            {
                "arm_group_label": "Cohort B - Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Healthy participants will receive a single oral dose of placebo."
            }, 
            {
                "arm_group_label": "Cohort C - LY2886721", 
                "arm_group_type": "Experimental", 
                "description": "Healthy participants will receive a single oral ascending dose of LY2886721 in at least 2 of 3 study periods."
            }, 
            {
                "arm_group_label": "Cohort C - Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Healthy participants will receive a single oral dose of placebo in up to 1 of 3 study periods."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being done for the following reasons:\n\n      To determine the safety of LY2886721 and any side effects that may be associated with it and\n      to see how much of the study drug is in the blood and the cerebrospinal fluid when one dose\n      is given to healthy participants and participants diagnosed with Alzheimer's disease. It\n      will also look at how safe and tolerable the study drug is when given to healthy\n      participants in higher doses.\n\n      This research study is being conducted in three groups, referred to as Groups (Cohorts) A, B\n      or C.\n\n      Group A will enroll participants with Alzheimer's disease while Groups B and C will enroll\n      healthy participants.\n\n      For Group A or B, participation in this research study could last up to  34 days. For Group\n      C, participation could last up to 60 days."
        }, 
        "brief_title": "A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Alzheimer Disease", 
            "Healthy Volunteers"
        ], 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy participants have a body mass index (BMI) of 19 to 32 kilograms per square\n             meter (kg/m^2), inclusive, at screening. There are no restrictions on BMI in\n             participants diagnosed with AD\n\n          -  Healthy participants should not be taking any concomitant medications. For\n             participants with AD, concomitant medications will be determined by the investigator\n             in consultation with the Lilly clinical pharmacologist on an individual basis\n\n        Cohort A:\n\n          -  Participants are defined as otherwise healthy males or females as determined by\n             medical history, physical examination and a diagnosis of AD and must be at least 45\n             years of age\n\n          -  Meets National Institute of Neurological and Communicative Disorders and\n             Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria\n             for probable AD; as determined by a clinician approved by the sponsor or designee\n\n          -  Mini Mental State Examination (MMSE) score of 16 through 28 at screening\n\n          -  Modified Hachinski Ischemia Scale (MHIS) score of <4\n\n          -  Capable of understanding and signing their own informed consent, in the opinion of\n             the investigator, or if the participant has a Legally Authorized Representative (LAR)\n             then the LAR must be capable of understanding and signing the assent form and the\n             participant may or may not sign the informed consent, as to be determined by the\n             investigator.\n\n          -  If receiving concurrent treatment with an acetylcholinesterase inhibitor (AChEI)\n             and/or memantine, has been on a stable dose for at least 4 weeks before Day 1. Dosing\n             must remain stable throughout the study. Note: If a participant has recently stopped\n             ACHEIs and/or memantine, he or she must have discontinued treatment for at least 4\n             weeks before Day 1\n\n        Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807026", 
            "org_study_id": "15107", 
            "secondary_id": "I4O-EW-BACX"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A - LY2886721", 
                    "Cohort B - LY2886721", 
                    "Cohort C - LY2886721"
                ], 
                "description": "Administered orally", 
                "intervention_name": "LY2886721", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort A - Placebo", 
                    "Cohort B - Placebo", 
                    "Cohort C - Placebo"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Safety, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects and Patients Diagnosed With Alzheimer's Disease", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-\u221e) of Plasma LY2886721", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 96 hours after administration of study drug"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of Plasma LY2886721", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 96 hours after administration of study drug"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-\u221e) of Cerebrospinal Fluid (CSF) LY2886721", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 36 hours after administration of study drug"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of CSF LY2886721", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 36 hours after administration of study drug"
            }, 
            {
                "measure": "Pharmacodynamics (PD): Cnadir of Plasma Amyloid \u03b2 (A\u03b2)1-40", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 96 hours after administration of study drug"
            }, 
            {
                "measure": "PD: Cnadir of CSF A\u03b2 1-40", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 36 hours after administration of study drug"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807026"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Cohort C: Mean QTcF Value at Cmax", 
            "safety_issue": "No", 
            "time_frame": "Predose up to 48 hours after administration of study drug"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}